A loss of Treg capacity to suppress effector CD4+CD25− T cells has been observed, prior to anti-TNF treatment for active RA, and a recovery of this defect was observed in patients who respond clinically to anti-TNF drugs with a quantitative increase in Treg frequencies post treatment [6]. This evidence concerns the gene TNF and rheumatoid arthritis.